Mode of secretion
|
IFNγ
|
Synaptic release (in vitro) |
[24–26] |
TNFα
|
Multidirectional release (in vitro) |
[25] |
TACE-mediated cleavage of transmembrane TNFα (in vitro) |
Reviewed in [38] |
IL-2
|
Synaptic release (in vitro) |
[25] |
Biochemical stability and proteolytic cleavage
|
IFNγ
|
Increased half-life by HS/heparin-mediated prevention of inactivating proteolytic cleavage (in vitro) |
[32, 33] |
Activating cleavage up to ten C-terminal amino acids (facilitated by HS/heparin-binding) (in vitro) |
[32, 33] |
TNFα
|
Instable trimers after membrane cleavage (in vitro) |
[41] |
Receptor-mediated clearance
|
IFNγ
|
Receptor expression modulation by internal and environmental factors such as TNFα and IL1β (in vitro) |
[27, 28] |
TNFα
|
TNFR1 and TNFR2 are expressed on distinct cell types and differ in their affinity to TNFα (in vitro/in vivo) |
Reviewed in [42] |
TACE-mediated cleavage of TNFRs (in vitro) |
[46] |
IL-2
|
Low, intermediate, and high affinity IL-2 receptor variants, expressed by distinct cell types (in vivo) |
Reviewed in [12] |
Receptor expression modulated by FoxP3 and TCR signaling (in vitro) |
Reviewed in [12] |
IL-2 spreading distance is influenced by the size of the Treg pool (in vitro, suggestive in vivo) |
[51] |
Shedding of the IL-2Rα chain mediated by tumor-cell derived metalloproteinases or as a result of T-cell activation (in vitro) |
[53, 54] |
Receptor-independent capture
|
IFNγ
|
PS-mediated catch and release by tumor cells (in vitro) |
[29] |
Galectin-3 mediated containment within the TME (in vivo) |
[31] |
HS- or heparin-binding of IFNγ (in vitro) |
Reviewed in [33] |
Restricted spreading into tissues following heparin I.V. injection (in vivo) |
[34] |
TNFα
|
Binding to biglycan, decorin, dermatan sulfate, fibronectin and laminin (in vitro) |
[43–45] |
Il-2
|
Binding to galectin-3, collagen and HS/heparin (in vitro) |
[31, 56, 57] |
Loops
|
IFNγ
|
IFNγ-induced IFNγ production in antigen-stimulated CD4+ T cells (in vitro) |
[35] |
TNFα
|
TNFα stimulation increases sTNFR levels (in vitro) |
[47] |
Il-2
|
IL-2 induced expression of IL-2R (in vitro) |
[52] |
Inhibition of IL-2 production upon IL-2R signalling (in vitro) |
[55] |